Enlivex receives Nasdaq delisting notice over bid price

Enlivex (NASDAQ:ENLV) received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement. The company, which completed a reverse share split, plans to appeal. Enlivex is developing Allocetra, an immunotherapy for age-related inflammatory conditions.

Original reporting
Published Oct 27, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ENLV
Bearish
high confidence
Mentioned
$ENLV
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ENLVBearishMed
01

Why it matters

The delisting notice introduces significant downside risk, but the appeal process may provide temporary trading continuity. Investors should monitor Nasdaq hearing outcomes and any subsequent compliance actions.

02

Market read

The news is highly relevant for ENLV shareholders and traders focused on micro‑cap biotech stocks, with immediate price pressure expected.

03

What to watch

Potential hidden cash from the prediction‑markets treasury strategy and any upcoming clinical data could mitigate the delisting risk.

Relevance 6/10Novelty 7/10Timing: effective today

Background

Enlivex Ltd. (NASDAQ:ENLV) received a Nasdaq delisting notice after failing to maintain the $1 minimum bid price for 30 consecutive business days. The company cannot use a 180‑day compliance period due to a recent 1‑for‑16 reverse split and has filed an appeal.

Company-level read

Ticker impact

$ENLVBearishHigh confidence
Context

Nasdaq issued a delisting notice to Enlivex after its shares failed to meet the $1 bid price for 30 days and it cannot use a compliance period due to a recent reverse split.

Expected impact

likely pressure as the market prices in the delisting risk and potential loss of Nasdaq listing

Evidence & confidence

A delisting notice is a material corporate action that typically triggers sell‑offs, especially for a micro‑cap with limited liquidity.

Market effects

Minimal impact on the broader biotech sector; the issue is company‑specific.

Limited to U.S. small‑cap and Nasdaq‑listed biotech investors.

Low global relevance; primarily affects ENLV shareholders.

Counterpoint

If ENLV successfully appeals, the stock could rebound sharply on relief rally.

Key entities

  • Enlivex Ltd.

    Developer of the Allocetra immunotherapy platform.

  • Nasdaq

    Issuer of the delisting notice under Listing Rule 5815.

Related articles

$ENLVMed

Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.